-
-
-
-
-
-
-
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
UroGen Pharma (URGN) Misses Q2 EPS by 22c
-
-
-
-
-
-
-
UroGen Pharma (URGN) Misses Q4 EPS by 3c
-
-
-
-
-
-
-
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
-
-
-
-
-
-
-
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
-
-
-
-
-
-
-
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
-
-
-
-
-
-
-
UroGen Pharma (URGN) Tops Q3 EPS by 3c
-
1,199,636 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

